Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Thoracic Malignancies
•
Medical Oncology
How do you discern between pseudo-progression or hyper-progression in patients with NSCLC or cancers treated with immune checkpoint inhibitors?
How common is hyperprogresion, and are there any strategies to mitigate it?
Related Questions
Did NRG LU004 demonstrate safety with hypofractionated lung radiation and concurrent ICI?
How would you manage a patient with radiation pneumonitis who remains symptomatic on steroids?
How would you treat a patient with progressive ALK (+) NSCLC that has MET Exon 14 deletion upon repeat molecular testing on metastatic site?
What is your approach for an RA patient with lung cancer who is starting immunotherapy?
Is there a role for nintedanib in the management of patients with radiation-induced pulmonary fibrosis?
For those early stage resectable NSCLC patients who received neoadjuvant chemoimmunotherapy as per Checkmate816 and did not attain a pCR, what are the adjuvant immunotherapy treatment strategies if EGFR negative?
How do the results of TROPION-Lung01 Phase III trial change your practice in the management of locally advanced or metastatic NSCLC?
How would you manage a patient with stage IV EGFR L858R mutation but with a debilitating drug rash from osimertinib?
How would you treat a patient with BRAF V600E-mutated metastatic lung adenocarcinoma who has progressed on chemotherapy, immunotherapy and Dabrafenib/Trametinib?
What initial therapy do you offer elderly patients with metastatic NSCLC with MET amplification and PD-L1 >50%?